ClinConnect ClinConnect Logo
Search / Trial NCT06883097

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 12, 2025

Trial Information

Current as of May 09, 2025

Not yet recruiting

Keywords

Tobacco Smoking Cessation Human Immunodeficiency Virus (Hiv) Tobacco Abstinence Quit Smoking

ClinConnect Summary

The Quitting Matters Human Immunodeficiency Virus Hybrid Trial is a research study designed to help people living with HIV who want to quit smoking. The study will compare two different smartphone apps that assist with quitting smoking, both of which will be used alongside nicotine replacement therapy (like patches and gum) to increase the chances of success. Participants will be involved for about six months, during which they will have five video calls with study staff to check on their progress and complete some questionnaires. They may also provide breath and saliva samples to measure their nicotine levels.

To join the study, participants must be at least 18 years old, have been smoking daily for the past month, and have a desire to quit. They should also be receiving care for HIV and own a smartphone. However, some individuals may not be eligible, such as those who are pregnant, have certain medical conditions, or are currently undergoing other smoking cessation treatments. This trial offers a chance to receive support for quitting smoking while also contributing to important research that could help others in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Self-reported daily cigarette smoking over the past 30 days
  • 2. Self-reported HIV status
  • 3. Age 18 or older
  • 4. Desire to quit smoking
  • 5. Willing and medically eligible to use NRT
  • 6. Currently receiving HIV care
  • 7. Currently owning an Android or iOS smartphone
  • Exclusion Criteria:
  • 1. Current acute psychotic episode or unsafe to participate in the study
  • 2. Pregnant or intending to become pregnant in the next 6 months
  • 3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
  • 4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
  • 5. Not able to fluently speak and write in English
  • 6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation

About Wake Forest University Health Sciences

Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.

Locations

Patients applied

0 patients applied

Trial Officials

Roger Vilardaga Viera, Ph.D.

Principal Investigator

Wake Forest University Health Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported